SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS

Judith J. Ochs, Ching Hong Pui, Clara Mason, W. Paul Bowman, Minnie Abromowitch, Joseph V. Simone

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Features of seizures in children with acute lymphoblastic leukaemia were examined in relation to the type of treatment received for central nervous system prophylaxis. Of the 1289 patients in the study, 132(10%) had experienced one or more seizures. In 96 the seizures had not been associated with any recognisable aetiology and, with 3 exceptions, had been generalised or focal motor in type. Status epilepticus had occurred in one-third of the group with seizures. Initial seizure rates among patients in continuous complete remission were significantly related to the method of central nervous system prophylaxis. Those who had received intrathecal methotrexate repeatedly with or without moderate doses of methotrexate intravenously or prior prophylactic cranial irradiation had a 20-fold higher seizure risk during remission induction, and a 37-fold higher risk during the 6th to 12th month of therapy, than did those who had received irradiation and only five intrathecal injections of methotrexate early in the course of treatment. Other clinical factors associated with an increased frequency of seizures were escalation of intravenous methotrexate dosage following cranial irradiation and treatment of meningeal leukaemia with intrathecal methotrexate. Parenterally administered methotrexate thus seems to increase susceptibility to seizure development in childhood leukaemia patients.

Original languageEnglish (US)
Pages (from-to)1422-1424
Number of pages3
JournalThe Lancet
Volume324
Issue number8417-8418
DOIs
StatePublished - Dec 29 1984

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Seizures
Methotrexate
Cranial Irradiation
Leukemia
Central Nervous System
Remission Induction
Spinal Injections
Status Epilepticus
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ochs, J. J., Pui, C. H., Mason, C., Bowman, W. P., Abromowitch, M., & Simone, J. V. (1984). SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS. The Lancet, 324(8417-8418), 1422-1424. https://doi.org/10.1016/S0140-6736(84)91621-0

SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS. / Ochs, Judith J.; Pui, Ching Hong; Mason, Clara; Bowman, W. Paul; Abromowitch, Minnie; Simone, Joseph V.

In: The Lancet, Vol. 324, No. 8417-8418, 29.12.1984, p. 1422-1424.

Research output: Contribution to journalArticle

Ochs, JJ, Pui, CH, Mason, C, Bowman, WP, Abromowitch, M & Simone, JV 1984, 'SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS', The Lancet, vol. 324, no. 8417-8418, pp. 1422-1424. https://doi.org/10.1016/S0140-6736(84)91621-0
Ochs JJ, Pui CH, Mason C, Bowman WP, Abromowitch M, Simone JV. SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS. The Lancet. 1984 Dec 29;324(8417-8418):1422-1424. https://doi.org/10.1016/S0140-6736(84)91621-0
Ochs, Judith J. ; Pui, Ching Hong ; Mason, Clara ; Bowman, W. Paul ; Abromowitch, Minnie ; Simone, Joseph V. / SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS. In: The Lancet. 1984 ; Vol. 324, No. 8417-8418. pp. 1422-1424.
@article{803c78495f8c4f5bb65de925302865ab,
title = "SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS",
abstract = "Features of seizures in children with acute lymphoblastic leukaemia were examined in relation to the type of treatment received for central nervous system prophylaxis. Of the 1289 patients in the study, 132(10{\%}) had experienced one or more seizures. In 96 the seizures had not been associated with any recognisable aetiology and, with 3 exceptions, had been generalised or focal motor in type. Status epilepticus had occurred in one-third of the group with seizures. Initial seizure rates among patients in continuous complete remission were significantly related to the method of central nervous system prophylaxis. Those who had received intrathecal methotrexate repeatedly with or without moderate doses of methotrexate intravenously or prior prophylactic cranial irradiation had a 20-fold higher seizure risk during remission induction, and a 37-fold higher risk during the 6th to 12th month of therapy, than did those who had received irradiation and only five intrathecal injections of methotrexate early in the course of treatment. Other clinical factors associated with an increased frequency of seizures were escalation of intravenous methotrexate dosage following cranial irradiation and treatment of meningeal leukaemia with intrathecal methotrexate. Parenterally administered methotrexate thus seems to increase susceptibility to seizure development in childhood leukaemia patients.",
author = "Ochs, {Judith J.} and Pui, {Ching Hong} and Clara Mason and Bowman, {W. Paul} and Minnie Abromowitch and Simone, {Joseph V.}",
year = "1984",
month = "12",
day = "29",
doi = "10.1016/S0140-6736(84)91621-0",
language = "English (US)",
volume = "324",
pages = "1422--1424",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8417-8418",

}

TY - JOUR

T1 - SEIZURES IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA PATIENTS

AU - Ochs, Judith J.

AU - Pui, Ching Hong

AU - Mason, Clara

AU - Bowman, W. Paul

AU - Abromowitch, Minnie

AU - Simone, Joseph V.

PY - 1984/12/29

Y1 - 1984/12/29

N2 - Features of seizures in children with acute lymphoblastic leukaemia were examined in relation to the type of treatment received for central nervous system prophylaxis. Of the 1289 patients in the study, 132(10%) had experienced one or more seizures. In 96 the seizures had not been associated with any recognisable aetiology and, with 3 exceptions, had been generalised or focal motor in type. Status epilepticus had occurred in one-third of the group with seizures. Initial seizure rates among patients in continuous complete remission were significantly related to the method of central nervous system prophylaxis. Those who had received intrathecal methotrexate repeatedly with or without moderate doses of methotrexate intravenously or prior prophylactic cranial irradiation had a 20-fold higher seizure risk during remission induction, and a 37-fold higher risk during the 6th to 12th month of therapy, than did those who had received irradiation and only five intrathecal injections of methotrexate early in the course of treatment. Other clinical factors associated with an increased frequency of seizures were escalation of intravenous methotrexate dosage following cranial irradiation and treatment of meningeal leukaemia with intrathecal methotrexate. Parenterally administered methotrexate thus seems to increase susceptibility to seizure development in childhood leukaemia patients.

AB - Features of seizures in children with acute lymphoblastic leukaemia were examined in relation to the type of treatment received for central nervous system prophylaxis. Of the 1289 patients in the study, 132(10%) had experienced one or more seizures. In 96 the seizures had not been associated with any recognisable aetiology and, with 3 exceptions, had been generalised or focal motor in type. Status epilepticus had occurred in one-third of the group with seizures. Initial seizure rates among patients in continuous complete remission were significantly related to the method of central nervous system prophylaxis. Those who had received intrathecal methotrexate repeatedly with or without moderate doses of methotrexate intravenously or prior prophylactic cranial irradiation had a 20-fold higher seizure risk during remission induction, and a 37-fold higher risk during the 6th to 12th month of therapy, than did those who had received irradiation and only five intrathecal injections of methotrexate early in the course of treatment. Other clinical factors associated with an increased frequency of seizures were escalation of intravenous methotrexate dosage following cranial irradiation and treatment of meningeal leukaemia with intrathecal methotrexate. Parenterally administered methotrexate thus seems to increase susceptibility to seizure development in childhood leukaemia patients.

UR - http://www.scopus.com/inward/record.url?scp=0021739083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021739083&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(84)91621-0

DO - 10.1016/S0140-6736(84)91621-0

M3 - Article

C2 - 6151043

AN - SCOPUS:0021739083

VL - 324

SP - 1422

EP - 1424

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8417-8418

ER -